$108.52
Value $189B
Abbott LaboratoriesvsBio-Techne
ABT and TECH stock compared: price, dividend, valuation and results, from SEC filings.
+1.18%
$72.80
Value $11.4B
Abbott Laboratories (ABT) has a market value of $189B and Bio-Techne (TECH) $11.4B. Over the last year, with dividends, ABT moved -13.7% and TECH +19.4%. The P/E is 40.1 for ABT and 66.5 for TECH. Dividend yield: ABT 2.32%, TECH 0.44%.
At a glance
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
ABT$189B
TECH$11.4B
ABT is 16 times TECH
Revenue, 12 months
ABT$48.2B
TECH$1.2B
ABT is 39 times TECH
Net income, 12 months
ABT$4.7B
TECH$172M
ABT is 27 times TECH
Operating margin
ABT13.8%
TECH19.6%
5.8 points apart
ROIC
ABT6.3%
TECH7.7%
1.4 points apart
P/E
ABT40.1
TECH66.5
TECH is 1.7 times ABT
Dividend yield
ABT2.3%
TECH0.4%
1.9 points apart
5-year return
ABT-6.7%
TECH-40.9%
34.2 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
The price over time
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
ABT-6.7%
TECH-40.9%
| Period | ABTWith dividends | TECHWith dividends |
|---|---|---|
| 1 year since November 12, 2025 | -13.7%Price -15.8% | +19.4%Price +18.6% |
| 3 years since November 13, 2023 | +20.7%+6.5% a yearPrice +13.3% | +29.5%+9.0% a yearPrice +27.5% |
| 5 years since November 12, 2021 | -6.7%-1.4% a yearPrice -15.5% | -40.9%-10.0% a yearPrice -42.3% |
| 10 years since November 15, 2016 | +228.9%+12.6% a yearPrice +172.6% | +190.5%+11.3% a yearPrice +174.4% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
Every figure
As on each company's page. A description, not a recommendation: no one figure says which is better.
ABTAbbott LaboratoriesTECHBio-Techne
Valuation
ABTTECH| Price | $108.52 | $72.80 |
|---|---|---|
| Market value | $189B | $11.4B |
| Enterprise value (EV) | $215B | $11.5B |
| P/E | 40.1 | 66.5 |
| P/E, 5-year median | 33.7 | 56.6 |
| P/B | 3.7 | 5.3 |
| EV/EBIT | 32.4 | 47.7 |
| Free cash flow yield | 3.6% | 2.7% |
Results and growth
ABTTECH| Revenue, 12 months | $48.2B | $1.2B |
|---|---|---|
| Net income, 12 months | $4.7B | $172M |
| Free cash flow, 12 months | $6.8B | $308M |
| Earnings per share, 12 months | $2.69 | $1.09 |
| Revenue growth, year on year | 5.7% | -0.4% |
| Revenue growth a year, past | +5.1%over 5 years | +5.5%over 5 years |
| EPS growth a year, past | +8.3%over 5 years | +5.9%over 5 years |
Margins and returns on capital
ABTTECH| Gross margin | 56.9% | 65.8% |
|---|---|---|
| Operating margin | 13.8% | 19.6% |
| Net margin | 9.8% | 14.0% |
| ROIC | 6.3% | 7.7% |
| ROE | 9.1% | 8.3% |
Balance sheet
ABTTECH| Cash | $4.3B | $350M |
|---|---|---|
| Total debt | $31.2B | $486M |
| Net debt / EBITDA | 3.3 | 0.2 |
| Interest cover | 6.7× | 27.2× |
Dividends and buybacks
ABTTECH| Dividend yield | 2.3% | 0.4% |
|---|---|---|
| Dividend per share, 12 months | $2.52 | $0.32 |
| Dividend growth a year, past | +10.4%over 5 years | +0.0%over 5 years |
| Buyback yield | 0.5% | 0.4% |
| Shareholder yield | 2.8% | 0.8% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
Which is bigger, Abbott Laboratories or Bio-Techne?
By market value, Abbott Laboratories ($189B) is about 16.5 times Bio-Techne ($11.4B), at today's prices.
How did ABT and TECH stock do over the last 10 years?
Since November 15, 2016, ABT's price moved +172.6% and TECH's +174.4%. With dividends: ABT +228.9% (+12.6% a year), TECH +190.5% (+11.3% a year). Past returns do not predict future ones.
Which pays the higher dividend, ABT or TECH?
The dividend yield at today's price is 2.32% for Abbott Laboratories and 0.44% for Bio-Techne. Over the last twelve months they paid $2.52 and $0.32 per share.
What is the P/E of ABT and TECH?
At today's price, the P/E is 40.1 for ABT and 66.5 for TECH. The median of the last five years was 33.7 and 56.6, which shows where each stands against its own past.
Which has the higher profit margins, Abbott Laboratories or Bio-Techne?
Over the last twelve months, the net margin was 9.8% for Abbott Laboratories and 14.0% for Bio-Techne, and the operating margin 13.8% and 19.6%. Revenue was $48.2B and $1.2B.
Which is the better investment, Abbott Laboratories or Bio-Techne?
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
Other comparisons
With each of the two, and with the largest in its sector.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
US stocksThe market today, the sectors, the largest companies and the week's results.The market's sectorsThe 11 sectors side by side: returns, share of the market, median P/E and dividend.Compare stocksTwo companies side by side: price over up to ten years, with and without dividends, and every figure.US dividend stocksEach dividend's yield next to whether the company's cash covers it and whether it was ever cut.
Descriptive data from SEC filings and market prices.